Vitamin D metabolism in acute and chronic cholestasis


From Addenbrooke’s Hospital, Cambridge, and Medical Research Council, Dunn Nutrition Unit, Cambridge

SUMMARY To study the effects of acute and chronic cholestasis on vitamin D metabolism we investigated six cases of acute extrahepatic obstructive jaundice and eight cases of primary biliary cirrhosis (PBC) (three supplemented with vitamin D). Plasma 25-hydroxyvitamin D (25OHD) was low in the patients with PBC un-supplemented with vitamin D but normal in obstructive jaundice. None of the patients with PBC showed radiological or histological evidence of osteomalacia. In PBC, dietary intake of vitamin D was low but response to ultra-violet irradiation of the skin was normal even in those with a considerably raised serum bilirubin. Patients with PBC or obstructive jaundice had low levels of 25 hydroxyvitamin D binding protein which correlated with the serum albumin. The half-life of intravenously injected $^3$H vitamin D$_3$ (3HD$_3$) and the subsequent production of $^3$H 25OHD were normal in all the patients with obstructive jaundice and in most with PBC. The two patients with PBC who produced less $^3$H 25OHD than expected were receiving vitamin D supplements. The urinary tritium ($^3$H) excretion after the injection of 3HD$_3$ correlated with the serum bilirubin. After the injection of $^3$H 25OHD$_3$ the urinary excretion of $^3$H was minimal and did not correlate with the serum bilirubin, suggesting that the radioactivity appearing in the urine after the $^3$H vitamin D$_3$ injection was associated with vitamin D metabolites other than 25OHD. Factors contributing to the low plasma 25OHD in primary biliary cirrhosis may be a low dietary intake of vitamin D, inadequate exposure to ultra-violet light, and a tendency to urinary wastage of vitamin D metabolites.

Osteomalacia is a well-recognised complication of liver disease especially in those with chronic cholestasis such as primary biliary atresia (PBA) and primary biliary cirrhosis (PBC) (Atkinson et al., 1956; Glasgow et al., 1976). In PBC, low levels of plasma 25OHD have been reported (Long et al., 1976; Wagonfeld et al., 1976) but the effect of cholestasis on vitamin D metabolism as distinct from that of hepatocellular dysfunction has yet to be clearly defined. The importance of cholestasis in the development of rickets is well illustrated in PBA where relief of the obstruction results in both a rise in the plasma 25 hydroxycholecalciferol (25OHD) and healing of the rickets, despite the continuing presence of biliary cirrhosis (Daum et al., 1976).

Animal experiments have suggested that cholestasis may affect 25 hydroxylation. Thus 25 hydroxylase activity as measured in rat liver homogenates is reduced by bile duct ligation for 21 days or by the addition of bile salts (Bolt et al., 1978). The finding in patients with PBC of a sub-normal rise in plasma 25OHD after the administration of parenteral vitamin D$_3$ has suggested an impairment of 25 hydroxylation (Wagonfeld et al., 1976); but a recent tracer study also in patients with PBC has shown no abnormality in the conversion of $^3$H cholecalciferol (3HD$_3$) to $^3$H 25OHD (Krawitt et al., 1977). To investigate further the effect of cholestasis on 25 hydroxylation in man we have studied the metabolism of intravenously injected 3HD$_3$ in patients with acute cholestasis due to extrahepatic bile duct obstruction as well as in patients with chronic cholestasis (PBC).

Malabsorption of vitamin D does occur in PBC (Krawitt et al., 1977) but this is unlikely to be a major cause of the low plasma 25OHD in this condition, as ultra-violet light is the more important source of
Vitamin D in man (Preece et al., 1975; Pittet et al., 1979; Poskitt et al., 1979). We have therefore also investigated the response of jaundiced patients with PBC to ultra-violet irradiation.

It has also been reported that the urinary excretion of tritium (³H) after the injection of ³HD₃ was increased in jaundiced patients with PBC; preliminary work suggested that this did not represent an increased excretion of 25OHHD₃ (Krawitt et al., 1977). We have further investigated this possibility by studying the urinary ³H excretion after the injection, on separate occasions, of ³HD₃ and ³H 25OHHD₃ in patients with acute and chronic cholestasis.

Methods

Eight patients with PBC proven by liver biopsy and six patients with acute extrahepatic obstructive jaundice were studied. The patients with PBC were all female, had a mean age of 55.9 ± 13.7 years (± SD) and had had symptoms for 25.5 ± 24.1 months. Three of these patients were receiving supplementary vitamin D. The group with acute extrahepatic obstructive jaundice consisted of three male and three female subjects with a mean age of 63.8 ± 9.5 years and had experienced symptoms for 1.0 ± 1.3 months. Three had carcinoma of the pancreas and three had gallstones.

All investigations were performed after approval by Addenbrooke's Hospital Ethical Committee and after fully informed consent had been obtained from the patients.

Dietary vitamin D intake was assessed by the recall technique (Burke, 1947). Bone biopsies were obtained from the iliac crest using a trephine needle in six patients with PBC. A bone biopsy was considered normal if there was an osteoid area of less than 5% with normal calcification fronts (Woods et al., 1968). Serum calcium, phosphate, alkaline phosphatase, bilirubin, and albumin (on 1000 mg calcium diet) were measured by Autoanalyser. Plasma 25OHHD was measured by a competitive protein binding assay (Edelstein et al., 1974).

25 hydroxyvitamin D binding protein (25OHDBP) was assayed by immunonephelometry using anti-Gc globulin (DAKO). This protein is now believed to be the same as Gc globulin (Bouillon et al., 1976) and the Dako antibody used has been shown to react only against the 25OHDBP (Dann, J. G., personal communication). Vitamin D₃ half-life and 25OHHD production were measured as previously described (Jung et al., 1978). Calcium absorption was measured by a forearm counting technique after seven days on a 10 mmol (400 mg) calcium diet (Chalmers et al., 1973). Urine was collected for 24 hours after the injection of 2.5 μC (1,2³H)D₃ or 2.5 μC (26,27³H) 25OHHD₃. 1 ml samples were treated with (5–14%) sodium hypoclorite (BDH) to reduce quenching. This process was shown not to reduce counts due to ³H. The aqueous solution was counted in a Triton/PPO/POPOP scintillator in a Packard 2425 liquid scintillation counter.

Response to ultra-violet light was assessed in four female control subjects and three patients with PBC. A total of 20 minutes' whole body exposure was given over four weeks using four Westinghouse FS40 lamps. One patient (see Table 2, PBC subject 3) aged 65 with stage IV PBC (Scheuer, 1973) was studied in detail during ultra-violet light exposure with ³HD₃ half-life measurements before and after ultra-violet irradiation.

Results

Biochemical Findings

Table 1 shows the biochemical findings in the patients with PBC and extrahepatic obstructive

---

**Table 1** Biochemical data

<table>
<thead>
<tr>
<th>Biochemical tests</th>
<th>Primary biliary cirrhosis</th>
<th>Extrahepatic obstructive jaundice</th>
<th>Normal range</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Non-Vitamin D supplemented (5)</td>
<td>Vitamin D2 supplemented (6)</td>
<td>Normal range</td>
</tr>
<tr>
<td>Calcium (mmol/l)</td>
<td>2.23 ± 0.20</td>
<td>2.18 ± 0.16</td>
<td>2.16 ± 0.11</td>
</tr>
<tr>
<td>Phosphate (mmol/l)</td>
<td>1.08 ± 0.14</td>
<td>1.17 ± 0.12</td>
<td>1.20 ± 0.12</td>
</tr>
<tr>
<td>Alkaline phosphate (IU/l)</td>
<td>875 ± 462</td>
<td>867 ± 711</td>
<td>652 ± 698</td>
</tr>
<tr>
<td>Albumin (g/l)</td>
<td>35 ± 6.2</td>
<td>32 ± 6.5</td>
<td>33.5 ± 7.2</td>
</tr>
<tr>
<td>Bilirubin (μmol/l)</td>
<td>161.4 ± 169.1</td>
<td>143.7 ± 187.4</td>
<td>161.5 ± 105.8</td>
</tr>
<tr>
<td>25OHDD (μmol/l)</td>
<td>13 ± 11.3</td>
<td>26.3 ± 8.3</td>
<td>21 ± 12.3</td>
</tr>
<tr>
<td>25OHDD binding protein (μg/ml)</td>
<td>223 ± 54</td>
<td>199.5 ± 24.7</td>
<td>235 ± 17</td>
</tr>
</tbody>
</table>

Mean ± SD.

Number of patients in parentheses.

Calcium: 1 mmol/l = 0.25 × mg/m 100 ml. Phosphate: 1 mmol/l = 0.323 × mg/100 ml.

Bilirubin: 1 μmol/l = 17.1 × mg/100 ml. 25OHDD: 1 nmol/l = 400 ng/l.
jaundice. Plasma 25OHD was significantly lower in the patients with PBC not receiving supplementary vitamin D compared with the controls (p < 0.05). In the patients with extrahepatic obstructive jaundice and those with PBC receiving supplementary vitamin D, the plasma 25OHD levels were similar to those of controls. Plasma 25OHD failed to correlate with the serum albumin, serum bilirubin, or duration of symptoms in PBC, although the latter did correlate with the serum bilirubin (r = 0.73, p < 0.05).

Low plasma 25OHDBP was found both in PBC and obstructive jaundice. There was a significant correlation of the plasma 25OHDBP with the serum albumin (r = 0.78, p < 0.01), but no correlation between plasma 25OHD and plasma 25OHD or 3H vitamin D half-life.

**INTAKE OF VITAMIN D AND ABSORPTION OF CALCIUM**

Dietary intake of vitamin D in the patients with PBC was low at 40 ± 24 IU/day (recommended intake 100 IU/day). 44Ca absorption was low in all patients with PBC (26.0 ± 9.8%, n.r. 25–72%) with no significant difference between those having vitamin D supplements and those not. No correlation was found between the plasma 25OHD and 44Ca absorption.

**BONE MORPHOLOGY**

Patients with PBC showed no evidence of osteomalacia or hyperparathyroidism on iliac crest biopsy and radiology showed no Looser’s zones or any new or old fractures.

**3H VITAMIN D STUDIES**

Previous studies have shown that in a normal population there is a negative correlation between the 3H3 clearance from plasma and the plasma 25OHD (Jung et al., 1978). In the patients with acute obstruction, the 3H3 half-life was appropriate to the plasma 25OHD level. Most of the patients with PBC also had an appropriate response, but two subjects, both with very low plasma 25OHD levels, had a 3H3 half-life longer than expected. The appearance of 3H 25OHD in the plasma four hours after the injection of 3H3 was also measured (Fig. 1) and in normal subjects a negative correlation exists between this and the vitamin 3H3 half-life (r = −0.68) (Jung et al., 1978). All the patients with acute obstruction had a normal response, as did the majority of patients with PBC. Two patients with PBC produced less 3H 25OHD than expected. Both were on supplementary vitamin D and had normal vitamin D half-lives.

Urinary 3H was counted after the injection of 3H3 in six patients with PBC and one with extrahepatic obstructive jaundice (Fig. 2). A positive correlation was found between serum bilirubin and urinary 3H (r = 0.8; p < 0.02). At normal levels of serum bilirubin very little radioactivity appeared in the urine and it was only at a serum bilirubin level of 30 μmol/l that urinary 3H rose above 1% of the injected dose. These patients urinary 3H was strongly correlated with 3H3 half-life (r = 0.86, p < 0.01). No relationship was found between urinary 3H and serum albumin.

**3H 25OHD3 STUDIES**

After 3H 25OHD3 was injected intravenously very little 3H appeared in the urine and there was no correlation with the serum bilirubin (Fig. 2). Most patients excreted less than 3% of the injected dose of 3H 25OHD3 but two people with serum bilirubins of 145 and 62 μmol/l (8.5 and 3.6 mg/100 ml) excreted 4.5% and 3.6% respectively.

**ULTRA-VIOLET LIGHT**

The response to ultra-violet light was examined in three patients with PBC (Table 2), two with severe jaundice and one with a slightly raised bilirubin. All three patients demonstrated a rise of plasma 25OHD similar to that seen in four normal subjects, the greatest rise occurring in the patient with the lowest initial plasma 25OHD level. This patient was studied in detail (Fig. 3). Bone biopsy showed no evidence of osteomalacia. The serum calcium was 1.98 mmol/l (7.9 mg/100 ml) albumin 25 g/l, phosphate 0.85 mmol/l (2.6 mg/100 ml), bilirubin 116 μmol/l (6.8 mg/100 ml), alkaline phosphatase 148 IU/l, and plasma 25OHD 4.3 nmol/l (1.7 μg/l). The plasma 25OHD level rose rapidly after starting ultra-violet therapy and was accompanied by a rise in serum calcium, phosphate, and alkaline phosphatase. 3H vitamin D half-life was 15.0 hours initially and rose to

<table>
<thead>
<tr>
<th>Patients</th>
<th>25OHD (nmol/l)</th>
<th>Bilirubin (μmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before</td>
<td>After</td>
</tr>
<tr>
<td>Controls</td>
<td>27</td>
<td>43</td>
</tr>
<tr>
<td>1</td>
<td>33.3</td>
<td>85</td>
</tr>
<tr>
<td>2</td>
<td>26.3</td>
<td>45.5</td>
</tr>
<tr>
<td>3</td>
<td>18.9</td>
<td>34</td>
</tr>
<tr>
<td>Primary biliary cirrhosis</td>
<td>28.5</td>
<td>36</td>
</tr>
<tr>
<td>1</td>
<td>28</td>
<td>38.3</td>
</tr>
<tr>
<td>2</td>
<td>4.3</td>
<td>37.5</td>
</tr>
</tbody>
</table>

Table 2: Response of plasma 25 hydroxycholecalciferol to ultra-violet irradiation
Vitamin D metabolism in acute and chronic cholestasis

Fig. 1 Relationship of the percentage dpm in plasma as $^3$H 25OHD at four hours after an intravenous injection of $^3$H cholecalciferol and $^3$H cholecalciferol half-life in patients with acute obstructive jaundice ($\triangle$) and primary biliary cirrhosis ($\bullet$). The regression line for normal subjects is shown ($r = -0.68, p < 0.01$). (1) and (2) represent the values in a patient with primary biliary cirrhosis before and after exposure to ultra-violet light (see also Fig. 3).

Table 3 Incidence of osteomalacia on bone biopsy in reported series of primary biliary cirrhosis

<table>
<thead>
<tr>
<th>Primary biliary cirrhosis</th>
<th>Histological criteria for osteomalacia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases (no.)</td>
<td>With osteomalacia</td>
</tr>
<tr>
<td>(no.)</td>
<td>(%)</td>
</tr>
<tr>
<td>Atkinson et al. (1956)</td>
<td>12</td>
</tr>
<tr>
<td>Kehayoglou et al. (1968)</td>
<td>12</td>
</tr>
<tr>
<td>Ajdukiewicz et al. (1974)</td>
<td>14</td>
</tr>
<tr>
<td>Long et al. (1978a)</td>
<td>20</td>
</tr>
<tr>
<td>Reed et al. (1977)</td>
<td>6</td>
</tr>
<tr>
<td>Compston et al. (1977)</td>
<td>11</td>
</tr>
<tr>
<td>Compston et al. (1978) (personal communication)</td>
<td>30</td>
</tr>
<tr>
<td>Jung et al. (to date)</td>
<td>6</td>
</tr>
<tr>
<td>Total</td>
<td>111</td>
</tr>
</tbody>
</table>
The percentage of $^3$H 25OHD appearing at four hours after the injection of $^3$HD$_3$ was 46·7% before ultra-violet light and 8·9% after treatment; a similar response to that seen in normal subjects before and after exposure to ultra-violet light.

Discussion

Despite the low levels of plasma 25OHD in our patients with PBC none showed evidence of osteomalacia on bone histology or radiology. This contrasts with other reports in which the incidence of osteomalacia in PBC has varied from 8 to 83% (mean=30·6%) (Table 3). This wide variation in incidence may be due to the different histological criteria used for the diagnosis of osteomalacia. As osteoid increases with age (Bordier and Tun Chot, 1972), care must be taken in interpreting the osteoid measurements, as in most reported series the mean age of the patients with PBC was over 50 years.

The present work demonstrates that $^3$H 25OHD production from injected $^3$HD$_3$ is normal in all patients with acute obstructive jaundice and the majority of patients with PBC. Although this observation confirms a previous report of normal 25 hydroxylation in PBC (Krawitt et al., 1977), it is at variance with the finding of a 48% reduction in 25 hydroxylase activity in liver homogenates from rats in which the bile duct had been ligated for 21 days (Bolt et al., 1978). This difference may well represent species variation. We found normal 25 hydroxylation in two patients with acute bile duct obstruction who had serum bilirubin levels of 300 and 360 $\mu$mol/l. Moreover, in PBC plasma 25OHD was not correlated with biochemical indices of hepatic function. The low 25OHD production found in two patients with PBC could indicate an impairment of 25 hydroxylation due to liver disease. An alternative explanation, as both were receiving supplementary vitamin D, is that it was due to a forward negative effect of a high liver vitamin D level on 25 hydroxylation (Mawer et al., 1977).

The fact that acute cholestasis does not result in a rapid reduction in the plasma 25OHD suggests that the reduced plasma 25OHD in PBC is related to the duration of cholestasis rather than to the severity of liver damage. It is unlikely that the low level of 25OHDBP found in patients with acute and chronic cholestasis is a cause of low plasma 25OHD as this binding protein is only 2–3% saturated in normal subjects and thus has a considerable reserve of binding capacity even in a reduced concentration (Haddad and Walgate, 1976).

We have confirmed the finding that the urinary excretion of $^3$H after the injection of $^3$HD$_3$ in PBC correlates with the serum bilirubin (Krawitt et al., 1977). We also found a similar relationship in acute
Vitamin D metabolism in acute and chronic cholestasis 845

Fig. 3 The biochemical response to ultra-violet light in a patient with primary biliary cirrhosis. The arrows indicate the days on which ultra-violet light was administered.

cholestasis. It is possible that this urinary radioactivity represents water-soluble metabolites which would normally be excreted in bile in subjects with intact biliary drainage. There is evidence for biliary excretion of vitamin D metabolites in normal man. Arnaud et al. (1975) found after intravenous injection of 3HCD3 that up to 10% of the radioactivity could be recovered from duodenal aspirates within six hours.

After injection of 3H 25OHD3, we found that very little radioactivity appeared in the urine even at high serum bilirubin concentrations and there was no correlation with the serum bilirubin. This suggests that the radioactivity excreted in urine after 3HCD3 injection represents metabolites of vitamin D, other than 25OHD3. This urinary radioactivity may represent metabolites normally produced in the liver and excreted in the bile, or an abnormal metabolism of vitamin D resulting in the increased formation of abnormal water-soluble metabolites. These urinary losses in cholestasis could deplete body stores of vitamin D, if vitamin D input were inadequate or borderline. The lack of any appreciable urinary excretion of radioactivity after an injection of 3H 25OHD3 even in severe cholestasis would tend to imply that very little 25OHD3 is normally excreted in the bile in a water-soluble form. Nevertheless, Arnaud et al. (1975) have reported that, in man, after an injection of (26-273H) 25OHD3, a third of the radioactivity appeared in duodenal aspirates within 24 hours. Results suggestive of an enterohepatic circulation of 25OHD3 have been found in rats (Sittrin et al., 1978) and rhesus monkeys (Rikkers, 1975). However, additional work is necessary to characterise the nature of the radioactivity appearing in bile after 3H 25OHD3 injection and the significance of a possible enterohepatic circulation of 25OHD3 in man.

As the plasma clearance and hydroxylation of 3HCD3 is normal, the low plasma 25OHD of chronic cholestasis may be due to a reduction in the input of vitamin D. We did find dietary intake of vitamin D to be low in PBC and absorption of vitamin D is likely to have been impaired in the presence of steatorrhoea (mean faecal fat was 54.8 ± 6.9 mmol per 24 hours). However, this low dietary intake would be important only if exposure or response to ultra-violet light were reduced, as the major source of vitamin D in man is ultra-violet irradiation. It has recently been shown that the ingestion of 200 IU of vitamin D3 per day for one month did not raise the plasma 25OHD significantly, whereas irradiation of 600 cm2 of skin for five minutes produced a significant increase in the plasma 25OHD (Poskitt et al., 1979; Davie and Lawson, in preparation). Also, plasma 25OHD has been shown to be significantly reduced in sailors submerged in nuclear submarines for several months despite adequate dietary intake of vitamin D (Preece et al., 1975). Fractionation studies on plasma 25OHD have shown that 84% of the total plasma 25OHD is 25OHD3, presumably derived mostly from sunlight (Haddad and Hahn, 1973).

We found a normal response to ultra-violet light in the three patients with PBC, despite a considerably raised serum bilirubin in two of the subjects. In the
patient studied in detail, where the serum bilirubin was 116 \( \mu \text{mol/l} \) (6.8 mg/100 ml), the rise in serum calcium and phosphate as well as in plasma 25OHD suggested a low vitamin D reserve, although the bone biopsy showed no evidence of osteomalacia. \(^3\text{H}\) 25OHD production from injected \(^3\text{HD}_3\) diminished appropriately as the plasma 25OHD rose and \(^3\text{HD}_3\) half-life became longer, again emphasising the normal 25 hydroxylation in PBC, even though the initial plasma 25OHD was low in this patient. The adequate response to ultra-violet light in these three patients suggests that the low 25OHD in PBC is due to inadequate exposure to sunlight. We have no evidence that jaundice may raise the threshold of response to ultra-violet light but this possibility will need to be excluded by further quantitative studies.

We conclude that, in acute and chronic cholestasis, 25 hydroxylation is normal but \(^3\text{H}\) excretion in urine is increased after injection of \(^3\text{HD}_3\). Increased excretion of vitamin D metabolites may be sufficient to deplete vitamin D reserves if input is inadequate. Although oral intake and absorption of vitamin D are low in PBC, input from the skin should be sufficient to maintain reserves (as the response to ultra-violet light is normal) unless exposure to sunlight is also inadequate. It is likely, therefore, that the development of osteomalacia in PBC is multifactorial. As 25- and 1\(^\alpha\)-hydroxylation (Long et al., 1978b) are normal, parenteral vitamin D or ultra-violet light should prevent osteomalacia in all cases.

**Addendum**

Since this manuscript was submitted for publication we have measured the urinary excretion of radioactivity after intravenous \(^3\text{H}\) 25OHD in an additional five jaundiced patients with acute biliary obstruction (two with complete obstruction). We have confirmed that very little radioactivity (less than 3%) appears in the urine even at serum bilirubin concentration as high as 200 \( \mu \text{mol/l} \) (11.7 mg/100 ml).

We thank all our volunteers for their co-operation and Mrs M. Shorthouse for technical assistance, and Dr D. G. D. Wight for reporting on the bone biopsies.

**References**


